Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

HCW starts Inozyme at buy; PT $33

H.C. Wainwright initiated coverage of Inozyme (NASDAQ:INZY) with a “buy” rating and $33 price target. The stock closed at $6.10 on Feb. 4. Inozyme is a rare disease biopharmaceutical company focused on developing...

February 7, 2022

Markets

Brookline starts Fusion Pharma at buy; PT $15

Brookline Capital Markets launched coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with a “buy” rating and $15 price target. The stock closed at $7.53 on Feb. 2. Fusion is a clinical-stage oncology company focused on...

February 2, 2022

Markets

Brookline starts IceCure at buy; PT $5.65

Brookline Capital Markets initiated coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $5.65. The stock closed at $2.59 on Feb. 1. IceCure is a commercial-stage medical device company...

February 2, 2022

Markets

Maxim recalibrates biotech; lowering PTs as industry multiples contract

In an industry wide series of research reports, Maxim Group analyst Jason McCarthy, Ph.D., lowered price targets on stocks in his coverage universe, saying industry multiples have contracted but company outlooks remain...

February 2, 2022

Markets

Analysts start Amylyx on strong ALS data and possible regulatory approval

Analysts for SVB Leerink and H.C. Wainwright launched coverage of Amylyx Pharmaceuticals (NASDAQ:AMLX) with “outperform” and “buy” ratings, and price targets of $50 and $35, respectively. The stock closed at $23.18 on...

February 1, 2022

Markets

Stifel starts Vigil Neuroscience at buy; PT $24

Stifel initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “buy” rating and $24 price target. The stock closed at $12.90 on Jan. 31. Vigil is focused on precision medicine approaches to treat dementia, with a...

February 1, 2022

Markets

Analysts up Checkpoint Therapeutics PT on positive pivotal data

Analysts for H.C. Wainwright and Cantor Fitzgerald raised their price targets for Checkpoint Therapeutics (NASDAQ:CKPT) to $26 and $20, respectively, after the company reported positive pivotal data with anti-PD-L1...

January 25, 2022

Markets

Stifel starts ViewRay at buy; PT $7

Stifel initiated coverage of ViewRay (NASDAQ:VRAY) with a “buy” rating and price target of $7, reflecting a multiple of 8.3 times estimated 2023 revenue of $130-million. The stock closed at $4.46 on Jan. 24. “We see...

January 25, 2022

Markets

Dawson James ups BioCardia to buy; PT $4

Dawson James upgraded BioCardia (NASDAQ:BCDA) to “buy” with a $4 price target, citing multiple clinical programs in heart failure and a business deal potential. The stock closed at $1.39 on Jan. 21. Analyst Jason...

January 24, 2022

Markets

BTIG cuts Acutus Medical to neutral from buy

BTIG downgraded Acutus Medical (NASDAQ:AFIB) to “neutral” from “buy” and removed its price target, citing a forecast of flat sales in 2022, among other things. The stock closed at $2.46 on Jan. 19. Acutus is a cardiac...

January 20, 2022

Markets

SVB Leerink ups Calithera to OP from MP; PT to $3 from $1

SVB Leerink upgraded Calithera Biosciences (NASDAQ:CALA) to “outperform” from “market perform” and raised its price target to $3 from $1. The stock closed at 49 cents on Jan. 19. “We conducted a deeper dive on...

January 20, 2022

Markets

Maxim starts Kiora Pharma at buy; PT $2.50

Maxim Group initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $2.50. The stock closed at 80 cents on Jan. 18. Kiora is developing ophthalmic medicines including, KIO-101...

January 19, 2022

Markets

Maxim starts INVO Bioscience at buy; PT $7

Maxim Group launched coverage of INVO Biosciences (NASDAQ:INVO) with a “buy” rating and $7 price target. The stock closed at $3.69 on Jan. 18. INVO is a commercial-stage company with the world’s first and only...

January 19, 2022

Markets

Maxim ups Daré Biosciences PT to $4 from $3

Maxim Group raised its price target for Daré Bioscience (NASDAQ:DARE) to $4 from $3, citing FDA approval of XACIATO vaginal gel as a treatment for bacterial vaginosis (BV) and a commercial launch in 2022. The stock...

January 18, 2022

Markets

Canaccord cuts Acutus Medical to hold; PT to $3

Canaccord Genuity downgraded Acutus Medical (NASDAQ:AFIB) to “hold” from “buy” and slashed its price target to $3 from $10, citing a financing/dilution risk. The stock closed at $3.02 on Jan. 13. Acutus is an arrhythmia...

January 14, 2022

Markets

Maxim starts Genenta Science at buy; PT $21

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12. Genenta is developing cancer therapeutics using an autologous ex...

January 13, 2022

Markets

Dawson James starts Bluejay Diagnostics at buy; PT $10

Dawson James Securities initiated coverage of Bluejay Diagnostics (NASDAQ:BJDX) with a “buy” rating and price target of $10. The stock closed at $2.74 on Jan. 11. Bluejay is focused on improving patient outcomes...

January 12, 2022

Markets

Analysts start Bionomics at OW, OP

Analysts for Cantor Fitzgerald and William Blair launched coverage of Bionomics (NASDAQ:BNOX) with “overweight” and “outperform” ratings, respectively. Australia-based Bionomics is a clinical-stage biopharmaceutical...

January 10, 2022

Markets

Maxim starts NeuroSense at buy; PT $7

Maxim Group initiated coverage of NeuroSense Therapeutics (NASDAQ:NRSN) with a “buy” rating and price target of $7. The stock closed at $2.53 on Jan. 6. NeuroSense is a clinical-stage company developing therapies for...

January 7, 2022

Markets

Maxim starts Quoin Pharma at buy; PT $5

Maxim Group initiated coverage of Quoin Pharmaceuticals (NASDAQ:QNRX) with a “buy” rating and price target of $5. The stock closed at $1.74 on Jan.6. Quoin is a clinical-stage company developing therapies for rare...

January 7, 2022

Markets

WB starts Nkarta at OP; fair-value estimate $35

William Blair launched coverage of Nkarta (NASDAQ:NKTX) with an “outperform” rating and fair-value estimate of $35. The stock closed at $14.27 on Jan. 5. Nkarta is developing allogeneic chimeric antigen receptor (CAR)...

January 6, 2022

Markets

WB starts Cardiff Oncology at outperform

William Blair initiated coverage of Cardiff Oncology (NASDAQ:CRDF) with an “outperform” rating. The stock closed at $6.43 on Jan.4. Cardiff is advancing on vansertib, a specific PLK1 inhibitor, which “we view as a...

January 5, 2022

Subscribe